GENMAB A/S
GNMSF$18.31B
Large CapNASDAQBiotechnology🇺🇸North America3.0K employees
Drugs in Pipeline
6
Phase 3 Programs
5
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
GNMSF News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
Epcoritamab
DLBCL
Zalutumumab
Head and Neck Neoplasms
Lenalidomide
Follicular Lymphoma (FL)
Rina-S
Non-small Cell Lung Cancer (NSCLC)
Investigator's Choice Chemotherapy
Diffuse Large B-cell Lymphoma
HuMax-CD4
Cutaneous T-Cell Lymphoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Epcoritamab | Phase 3 | DLBCL | - | - |
Zalutumumab | Phase 3 | Head and Neck Neoplasms | - | - |
Lenalidomide | Phase 3 | Follicular Lymphoma (FL) | - | - |
Rina-S | Phase 3 | Non-small Cell Lung Cancer (NSCLC) | - | - |
Investigator's Choice Chemotherapy | Phase 3 | Diffuse Large B-cell Lymphoma | - | - |
HuMax-CD4 | Phase 2 | Cutaneous T-Cell Lymphoma | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply